Observatory of Pulmonary Arterial Hypertension of Congenital Heart Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

349 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-31

Study Completion Date

2022-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The complex congenital cardiac malformations are a significant number of different diseases, each having specific natural histories. The interface with pulmonary arterial hypertension (HTAP) is high since the physiology of many of these disorders comprises alterations in pulmonary vasculature.

This observatory is a cohort of 400 patients enrolled in 3 years, older than one month, having been informed and have agreed to participate in the study and with congenital heart disease other than patent foramen ovale as well as a diagnosis of pulmonary hypertension confirmed by cardiac catheterization.

The main objectives of this report are to know

* Incidence of congenital heart disease in HTAP France.
* Describe the natural history of HTAP in a large population of patients Congenital heart disease in France
* The characteristics of HTAP congenital heart disease
* Having a cohort study

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

French Hypertrophic Cardiomyopathy Observatory

NCT01091480

Hypertrophic Cardiomyopathy

RECRUITING

Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and Pediatric Patients With Congenital Heart Disease

NCT06784687

Congenital Heart Disease Cardiomyopathy Pulmonary Arterial Hypertension +1 more

COMPLETED

Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy

NCT04083729

Pulmonary Hypertension

UNKNOWN NA

Prognosis in Adult Patients with Congenital Heart Disease

NCT06723704

Adult Congenital Heart Disease

RECRUITING

Correlation of Right Atrial Strain With Pulmonary Hypertension, Right Ventricular Function And Outcome In Pediatric Patients

NCT05699681

Pulmonary Hypertension

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension of Congenital Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HTAP of Congenital Heart Disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient has a congenital heart disease other than patent foramen ovale
* The diagnosis of pulmonary hypertension was confirmed by cardiac catheterization. Only patients with Eisenmenger syndrome can be included without catheterization.
* The catheterization was done after 1 January 2009
* A mean pulmonary artery pressure \> 25 mm Hg
* Pulmonary vascular resistances \> 3 piece Wood m2
* Pulmonary capillary pressure available
* Consent for inclusion in the study must be signed by parents or legal guardians for minors, by the patient for adults.
* The patient he had a surgical procedure or interventional catheterization cardiac catheterization between his diagnosis and inclusion in the observatory? If yes, it can only be included if a new catheterization confirmed the persistence of HTAP at least 6 months after the procedure.
* Patient follow-up (at least once a year) in the center for its HTAP associated with congenital heart disease its

Minimum Eligible Age

1 Month

Eligible Sex

ALL

Accepts Healthy Volunteers

No